Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Diclofenac Gel for Breakthrough Pain and the Neuropathic Components of Pain in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 20-75~* Unilateral or bilateral knee osteoarthritis (OA), confirmed radiographically.~* Patients taking oral non-steroidal anti-inflammatory drugs (NSAIDs) in the amount and schedule prior to the breakthrough period will be permitted.~Exclusion Criteria:~* Patients with clinical history of anterior cruciate ligament (ACL) involvement.~* Patients on tricyclic antidepressants or anticonvulsants (neuropathic medications)~* History of ulcers or gastrointestinal (GI) bleeding~* Coagulation disorders~* Hypersensitivity to Aspirin or NSAIDS~* Congestive Heart Failure and Edema~* Advanced renal disease~* Aspirin triad~* Pregnant women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diclofenac gel (Type: OTHER): Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).